Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
View original at finance.yahoo.comMerck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches First presentation for MK-1045, a novel CD19xCD3 T-cell engager in patients with certain types of leukemia and lymphoma, and for bomedemstat, an LSD1 inhibitor, in patients with…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
The data shared at ASH 2025 reflect the continued growth and evolution of Merck's promising hematology pipeline
80% confidenceMerck aspires to be the premier research-intensive biopharmaceutical company in the world
80% confidenceMerck continues to build on its leadership in oncology by advancing a diverse portfolio of investigational candidates and exploring novel modalities with the goal of improving outcomes and helping to address significant unmet needs for patients with hematologic neoplasms and malignancies
80% confidenceThere can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful
80% confidence